Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |17 April 2007

Combination Inhaler Therapy for Chronic Obstructive Pulmonary Disease Free

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information

  • The summary below is from the full report titled “Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone–Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease. A Randomized Trial.” It is in the 17 April 2007 issue of Annals of Internal Medicine (volume 146, pages 545-555). The authors are S.D. Aaron, K.L. Vandemheen, D. Fergusson, F. Maltais, J. Bourbeau, R. Goldstein, M. Balter, D. O'Donnell, A. McIvor, S. Sharma, G. Bishop, J. Anthony, R. Cowie, S. Field, A. Hirsch, P. Hernandez, R. Rivington, J. Road, V. Hoffstein, R. Hodder, D. Marciniuk, D. McCormack, G. Fox, G. Cox, H.B. Prins, G. Ford, D. Bleskie, S. Doucette, I. Mayers, K. Chapman, N. Zamel, and M. FitzGerald, for the Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium.


Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • What is the problem and what is known about it so far?
    • Why did the researchers do this particular study?
    • Who was studied?
    • How was the study done?
    • What did the researchers find?
    • What were the limitations of the study?
    • What are the implications of the study?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link

What is the problem and what is known about it so far?

Chronic obstructive pulmonary disease (COPD) is a disease of the lungs that is usually caused by smoking. People with COPD are short of breath. They sometimes have spasms of the lung's airways (bronchial tubes), and they cough and wheeze. Symptoms and lung damage slowly get worse over time. Most patients also have bouts of worsening of symptoms. We call these bouts exacerbations. Doctors use several drugs to treat COPD. Many come in the form of inhalers or puffers. In an inhaler, the drugs are in solutions in small pressurized cans that have pumps. Patients put the pump's mouthpiece in their mouth and push the pump as they start to inhale deeply. They then hold their breath for about 10 seconds so that the airways absorb the medicine. The standard metered-dose inhaler releases a fixed dose of medicine in aerosol form. Examples of drug inhalers include tiotropium (known by the brand name Spiriva), salmeterol (known by the brand name Serevent), and a combination of fluticasone and salmeterol (known by the brand name Advair). Drugs in these inhalers have different actions. Tiotropium and salmeterol expand (dilate) the bronchial tubes. Fluticasone, a steroid, fights inflammation.

Why did the researchers do this particular study?

To see which of 3 inhaler regimens best prevented exacerbations in patients with COPD.

Who was studied?

449 adults with moderate to severe COPD. All patients were older than 35 years of age and had smoked cigarettes for many years.

How was the study done?

Researchers recruited patients from 27 academic and community medical centers in Canada. They randomly assigned patients to receive 1 of the 3 following regimens: tiotropium plus placebo, tiotropium plus salmeterol, or tiotropium plus the combination of fluticasone and salmeterol. The researchers, doctors, and patients did not know who received which treatment. Patients were followed for 1 year. The researchers then compared exacerbations, lung function, and hospitalizations among the groups.

What did the researchers find?

The proportion of patients who had exacerbations was 63% in the group given tiotropium plus placebo, 65% in the group given tiotropium plus salmeterol, and 60% in the group given tiotropium plus the combination of fluticasone and salmeterol. Patients given tiotropium plus the combination of fluticasone and salmeterol had better lung function, better quality of life, and fewer hospitalizations than those given tiotropium plus placebo. Lung function and hospitalization rates did not differ much between patients given tiotropium plus placebo and those given tiotropium plus salmeterol.

What were the limitations of the study?

More than 40% of the patients given tiotropium plus placebo and those given tiotropium plus salmeterol stopped using their inhalers before the study ended.

What are the implications of the study?

Adding the combination of fluticasone and salmeterol to tiotropium improved lung function and quality of life and decreased hospitalizations, but it did not affect the number of exacerbations in patients with moderate or severe COPD.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Combination Inhaler Therapy for Chronic Obstructive Pulmonary Disease. Ann Intern Med. 2007;146:I–12. doi: https://doi.org/10.7326/0003-4819-146-8-200704170-00153

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2020

×
Permissions

Published: Ann Intern Med. 2007;146(8):I-12.

DOI: 10.7326/0003-4819-146-8-200704170-00153

©
2007 American College of Physicians
0 Citations
Advertisement

See Also
Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone–Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: A Randomized Trial
View MoreView Less

Related Articles
Review: Corticosteroid plus LABA inhalers, vs LABAs alone, reduce morbidity in COPD
Annals of Internal Medicine; 158 (4): JC9
Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone–Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: A Randomized Trial
Annals of Internal Medicine; 146 (8): 545-555
Cardioselective β-Blockers in Patients with Reactive Airway Disease: A Meta-Analysis
Annals of Internal Medicine; 137 (9): 715-725
In symptomatic COPD, once-daily triple vs dual therapy reduced moderate or severe exacerbations at 1 year
Annals of Internal Medicine; 169 (4): JC16
View MoreView Less

Journal Club
Review: Corticosteroid plus LABA inhalers, vs LABAs alone, reduce morbidity in COPD
Annals of Internal Medicine; 158 (4): JC9
In symptomatic COPD, once-daily triple vs dual therapy reduced moderate or severe exacerbations at 1 year
Annals of Internal Medicine; 169 (4): JC16
In COPD, long-term use of higher doses of inhaled corticosteroids was linked to increased fracture risk
Annals of Internal Medicine; 168 (12): JC71
In COPD, new use of long-acting bronchodilators was linked to CV events at ≤ 30 days, but not > 30 days
Annals of Internal Medicine; 168 (8): JC47
View MoreView Less

Related Point of Care
Chronic Obstructive Pulmonary Disease
Annals of Internal Medicine; 154 (7): ITC4-1
Chronic Obstructive Pulmonary Disease
Annals of Internal Medicine; 148 (5): ITC3-1
View MoreView Less

Related Topics
Chronic Obstructive Airway Disease
Pulmonary/Critical Care

Chronic Obstructive Airway Disease, Pulmonary/Critical Care.

PubMed Articles
Pathogenesis of obstructive sleep apnea in individuals with the COPD + OSA Overlap syndrome versus OSA alone.
Physiol Rep 2020;8(3):e14371.
Development of an Aerosol Dose Collection Apparatus for In Vitro Dissolution Measurements of Orally Inhaled Drug Products.
AAPS J 2020;22(2):47.
View More

Results provided by: PubMed

Advertisement
CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2020 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×